Alpha-9 Oncology Inc.

About Alpha-9 Oncology Inc.

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company focused on advancing a distinctive portfolio of molecules for cancer treatment. Using targeted, bespoke molecules, they aim to treat cancer cells with precision, illuminating new possibilities in precision medicine.

Products & Services

Radiopharmaceuticals:Targeted molecules designed to treat cancer with precision, utilizing a bespoke, iterative process to optimize components like binder, linker, chelator, and radioisotope.

Specialties

Radiopharmaceuticals Oncology Drug Development Precision Medicine

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 175000000 MR: - FA: $175 Million FAN: 175000000	D: 2024-10-23 FD: 2024-10-23	15 investors

Series C Latest

2024-10-23

$175.0M

15 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

François Bénard

Co-Founder

K

Kuo-Shyan Lin

Head of Radiochemistry Program at BC Cancer

D

David Perrin

Professor of Chemistry

A

Alison Fleming

COO and Interim CEO

M

Matthias Jaffe

Chief Financial Officer

R

Robert Meehan

CMO

View 7 more team members with Pro

Unlock Full Team Directory

Recent News